東華大學圖書館 |

Language: English

Help

回圖書館首頁

手機版館藏查詢

Back

Switch To: Labeled | MARC Mode | ISBD

Cancer policy = pharmaceutical safety /

McKoy, June M.

Linked to FindBook

Google Book

Amazon

博客來

Cancer policy = pharmaceutical safety /

Record Type:	Electronic resources : Monograph/item
Title/Author:	Cancer policy/ edited by June M. McKoy, Dennis P. West.
Reminder of title:	pharmaceutical safety /
other author:	McKoy, June M.
Published:	Cham :Springer International Publishing : : 2019.,
Description:	v, 128 p. :ill., digital ;24 cm.
[NT 15003449]:	Pharmacovigilance programs: Do they improve Cancer Drug Safety? -- Impact of Cost on the Safety of Cancer pharmaceuticals -- Assessing pharmaceutical safety in Geriatric Oncology -- Cancer co-Morbidity: Implications for Drug Safety -- Statistical aids to signal generation: Are they effective in Identifying Adverse Cancer Drug Reactions? -- Pharmacovigilance of alternative medications in the Cancer Setting -- Key elements in Adverse Drug Interaction Safety Signals: evaluation of individual case reports in oncology -- Biosimilars: Are they really safe? -- Natural Language processing: improving the identification and communication of Cancer Drug Safety -- The Drug Shortage Crisis in the United States: Impact on cancer pharmaceutical safety -- Anatomy of Risk Evaluation and Mitigation Strategies (REMS) -- Cancer Drug Toxicity: Moving from patient to Survivor.
Contained By:	Springer eBooks
Subject:	Drugs - Safety measures. -
Online resource:	https://doi.org/10.1007/978-3-319-43896-2
ISBN:	9783319438962

Cancer policy = pharmaceutical safety /
Cancer policypharmaceutical safety /[electronic resource] :edited by June M. McKoy, Dennis P. West. - Cham :Springer International Publishing :2019. - v, 128 p. :ill., digital ;24 cm. - Cancer treatment and research,v.1710927-3042 ;. - Cancer treatment and research ;v.171..

Pharmacovigilance programs: Do they improve Cancer Drug Safety? -- Impact of Cost on the Safety of Cancer pharmaceuticals -- Assessing pharmaceutical safety in Geriatric Oncology -- Cancer co-Morbidity: Implications for Drug Safety -- Statistical aids to signal generation: Are they effective in Identifying Adverse Cancer Drug Reactions? -- Pharmacovigilance of alternative medications in the Cancer Setting -- Key elements in Adverse Drug Interaction Safety Signals: evaluation of individual case reports in oncology -- Biosimilars: Are they really safe? -- Natural Language processing: improving the identification and communication of Cancer Drug Safety -- The Drug Shortage Crisis in the United States: Impact on cancer pharmaceutical safety -- Anatomy of Risk Evaluation and Mitigation Strategies (REMS) -- Cancer Drug Toxicity: Moving from patient to Survivor.

Cancer Policy: Pharmaceutical Safety provides invaluable information on the interesting and compelling field of cancer drug safety. Identifying and understanding high-priority policy issues and key pharmacovigilance strategies is of paramount importance. In this volume, outstanding and original chapters provide an overview and synthesis of the latest thoughts and findings relating to drug safety in the cancer domain. Topics include natural language processing and pharmacovigilance of alternative cancer pharmaceuticals. The information presented in this volume will improve understanding of emerging strategies to identify adverse drug reactions and drug-drug interactions within the cancer setting and will highlight policies that have been instituted to improve cancer patient safety. In summary, Cancer Policy: Pharmaceutical Safety explores many of the important areas of pharmacovigilance research in oncology.

ISBN: 9783319438962

Standard No.: 10.1007/978-3-319-43896-2doiSubjects--Topical Terms:

916099
Drugs
--Safety measures.

LC Class. No.: RM301.15

Dewey Class. No.: 615.1

Cancer policy = pharmaceutical safety /
LDR:02803nmm a2200337 a 4500 001 2179002
003 DE-He213
005 20190715172143.0
006 m d
007 cr nn 008maaau
008 191122s2019 gw s 0 eng d
020 $a 9783319438962 $q (electronic bk.)
020 $a 9783319438948 $q (paper)
024 7 $a 10.1007/978-3-319-43896-2 $2 doi
035 $a 978-3-319-43896-2
040 $a GP $c GP
041 0 $a eng
050 4 $a RM301.15
072 7 $a MJCL $2 bicssc
072 7 $a MED062000 $2 bisacsh
072 7 $a MJCL $2 thema
082 0 4 $a 615.1 $2 23
090 $a RM301.15 $b .C215 2019
245 0 0 $a Cancer policy $h [electronic resource] : $b pharmaceutical safety / $c edited by June M. McKoy, Dennis P. West.
260 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2019.
300 $a v, 128 p. : $b ill., digital ; $c 24 cm.
490 1 $a Cancer treatment and research, $x 0927-3042 ; $v v.171
505 0 $a Pharmacovigilance programs: Do they improve Cancer Drug Safety? -- Impact of Cost on the Safety of Cancer pharmaceuticals -- Assessing pharmaceutical safety in Geriatric Oncology -- Cancer co-Morbidity: Implications for Drug Safety -- Statistical aids to signal generation: Are they effective in Identifying Adverse Cancer Drug Reactions? -- Pharmacovigilance of alternative medications in the Cancer Setting -- Key elements in Adverse Drug Interaction Safety Signals: evaluation of individual case reports in oncology -- Biosimilars: Are they really safe? -- Natural Language processing: improving the identification and communication of Cancer Drug Safety -- The Drug Shortage Crisis in the United States: Impact on cancer pharmaceutical safety -- Anatomy of Risk Evaluation and Mitigation Strategies (REMS) -- Cancer Drug Toxicity: Moving from patient to Survivor.
520 $a Cancer Policy: Pharmaceutical Safety provides invaluable information on the interesting and compelling field of cancer drug safety. Identifying and understanding high-priority policy issues and key pharmacovigilance strategies is of paramount importance. In this volume, outstanding and original chapters provide an overview and synthesis of the latest thoughts and findings relating to drug safety in the cancer domain. Topics include natural language processing and pharmacovigilance of alternative cancer pharmaceuticals. The information presented in this volume will improve understanding of emerging strategies to identify adverse drug reactions and drug-drug interactions within the cancer setting and will highlight policies that have been instituted to improve cancer patient safety. In summary, Cancer Policy: Pharmaceutical Safety explores many of the important areas of pharmacovigilance research in oncology.
650 0 $a Drugs $x Safety measures. $3 916099
650 0 $a Cancer $x Treatment. $3 618125
650 0 $a Pharmaceutical industry. $3 630829
650 0 $a Pharmaceutical policy. $3 630828
650 1 4 $a Oncology. $3 751006
650 2 4 $a Drug Safety and Pharmacovigilance. $3 2108855
700 1 $a McKoy, June M. $3 3383720
700 1 $a West, Dennis P. $3 3383721
710 2 $a SpringerLink (Online service) $3 836513
773 0 $t Springer eBooks
830 0 $a Cancer treatment and research ; $v v.171. $3 3383722
856 4 0 $u https://doi.org/10.1007/978-3-319-43896-2
950 $a Medicine (Springer-11650)